Carballo-Pedrares Natalia, Ponti Federica, Lopez-Seijas Junquera, Miranda-Balbuena Diego, Bono Nina, Candiani Gabriele, Rey-Rico Ana
Gene & Cell Therapy Research Group (G-CEL). Centro Interdisciplinar de Química y Biología - CICA, Universidade da Coruña, As Carballeiras, S/N. Campus de Elviña, 15071 A, Coruña, Spain.
genT_LΛB, Department of Chemistry, Materials and Chemical Engineering "G. Natta", Politecnico Di Milano, 20131, Milan, Italy.
J Biol Eng. 2023 Jul 25;17(1):49. doi: 10.1186/s13036-023-00363-7.
In recent decades, human mesenchymal stem cells (hMSCs) have gained momentum in the field of cell therapy for treating cartilage and bone injuries. Despite the tri-lineage multipotency, proliferative properties, and potent immunomodulatory effects of hMSCs, their clinical potential is hindered by donor variations, limiting their use in medical settings. To address this challenge, gene delivery technologies have emerged as a promising approach to modulate the phenotype and commitment of hMSCs towards specific cell lineages, thereby enhancing osteochondral repair strategies. This review provides a comprehensive overview of current non-viral gene delivery approaches used to engineer MSCs, highlighting key factors such as the choice of nucleic acid or delivery vector, transfection strategies, and experimental parameters. Additionally, it outlines various protocols and methods for qualitative and quantitative evaluation of their therapeutic potential as a delivery system in osteochondral regenerative applications. In summary, this technical review offers a practical guide for optimizing non-viral systems in osteochondral regenerative approaches. hMSCs constitute a key target population for gene therapy techniques. Nevertheless, there is a long way to go for their translation into clinical treatments. In this review, we remind the most relevant transfection conditions to be optimized, such as the type of nucleic acid or delivery vector, the transfection strategy, and the experimental parameters to accurately evaluate a delivery system. This survey provides a practical guide to optimizing non-viral systems for osteochondral regenerative approaches.
近几十年来,人间充质干细胞(hMSCs)在治疗软骨和骨损伤的细胞治疗领域得到了广泛应用。尽管hMSCs具有三系多能性、增殖特性和强大的免疫调节作用,但其临床应用潜力受到供体差异的限制,这限制了它们在医疗环境中的使用。为应对这一挑战,基因递送技术已成为一种有前景的方法,可调节hMSCs的表型并使其向特定细胞谱系定向分化,从而增强骨软骨修复策略。本综述全面概述了目前用于工程化改造间充质干细胞的非病毒基因递送方法,重点介绍了核酸或递送载体的选择、转染策略和实验参数等关键因素。此外,还概述了各种定性和定量评估其作为骨软骨再生应用递送系统治疗潜力的方案和方法。总之,本技术综述为优化骨软骨再生方法中的非病毒系统提供了实用指南。hMSCs是基因治疗技术的关键目标群体。然而,将其转化为临床治疗仍有很长的路要走。在本综述中,我们提醒需要优化最相关的转染条件,如核酸或递送载体的类型、转染策略以及准确评估递送系统的实验参数。本调查为优化骨软骨再生方法的非病毒系统提供了实用指南。